Lat­est news: It’s a no on uni­ver­sal boost­ers; Pa­tient death stuns gene ther­a­py field; In­side Tril­li­um’s $2.3B turn­around; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

Next week is shap­ing up to be a busy one, as our ed­i­tor-in-chief John Car­roll and man­ag­ing ed­i­tor Kyle Blanken­ship lead back-to-back dis­cus­sions with a great group of ex­perts to dis­cuss the week­end news and trends. John will be spend­ing 30 min­utes with Jake Van Naar­den, the CEO of Lil­ly On­col­o­gy, and Kyle has a bril­liant pan­el lined up: Har­vard’s Cigall Kadoch, Su­san Gal­braith, the new head of can­cer R&D at As­traZeneca, Roy Baynes at Mer­ck, and James Chris­tensen at Mi­rati. Don’t miss out on the ac­tion — sign up here.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.